Dupuytren Research Group Inc (EIN 263886958) - Form 990 Financial Analysis & Trantor Score

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2015

Legal Domicile

Principal Officer

DR Charles Eaton

Phone

5614298279

Tax Period

2024-07-01 to 2025-06-30

Dupuytren Research Group Inc, founded in 2015, is a small nonprofit in the Diseases & Disorders sector that reported $287K in total revenue in fiscal year 2024. Revenue grew 10% year-over-year, indicating healthy expansion. The organization ran a surplus of $119K, a strong 41% operating margin.

Mission

Our Mission is to do whatever is needed to develop and test preventive treatments for Dupuytren disease and related conditions. Our core effort focuses on answering the greatest need in Dupuytren treatment: developing a Dupuytren blood test.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2024)

Revenue Breakdown

Contributions & Grants $251,934

Program Service Revenue $0

Investment Income $35,367

Other Revenue $0

TOTAL REVENUE $287,301

Expense Breakdown

Grants Paid $0

Salaries & Benefits $0

Fundraising Expenses $7,118

Program Expenses $106,628

Other Expenses $168,766

TOTAL EXPENSES $168,766

Year-over-Year Comparison

	2024	2023	Change
Revenue	$287,301	$261,908	+0.1%
Expenses	$168,766	$166,423	+0.0%
Net Income	$118,535	$95,485	+0.2%

Key Indicators

✗ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✗ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

N/A

Volunteers

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
DR Charles Eaton	Executive Director	50.00	Officer Director	$0	$0	$0
Tom Hardart	Director	2.00	Director	$0	$0	$0
Keither Raskin MD	Director	2.00	Director	$0	$0	$0
Stuart Landow	Director	2.00	Director	$0	$0	$0
Laura Holmes Jost	Director	2.00	Director	$0	$0	$0
Gary Pess MD	Director	2.00	Director	$0	$0	$0
Peter Geimer	Director	2.00	Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2025	$287,301	$168,766	$847,586	$118,535
2024	$261,908	$166,423	$719,801	$95,485
2023	$219,098	$187,358	$625,020	$31,740
2022	$197,762	$225,604	$595,262	$-27,842
2021	$174,941	$270,745	$624,946	$-95,804
2020	$399,852	$142,918	$717,384	$256,934
2018	$197,863	$120,489	$391,131	$77,374

Dupuytren Research Group Inc